Stater Bros. announces tamoxifen giveaway for breast cancer patients
SAN BERNARDINO, Calif, Supermarket chain Stater Bros. is marking National Breast Cancer Awareness Month in October by giving away a drug used to treat the disease.
The chain announced Monday that it would provide 30-day supplies of the drug tamoxifen for free to patients with valid prescriptions at all of its 28 stores.
“At some point in their lives, almost everyone has been affected by cancer,” Stater Bros. chairman and CEO Jack Brown. “Stater Bros. Supermarkets believes in doing the right thing for the right reason, and we are so proud to be able to assist in the fight against cancer by offering this medication free of charge to those brave women battling this disease.”
Four-star general to deliver keynote address at NACDS Foundation’s annual dinner
ALEXANDRIA, Va. The charitable arm of the National Association of Chain Drug Stores announced that a four-star general will deliver the keynote address at its annual dinner.
General Stanley McChrystal, a former commander of U.S. and international forces in Afghanistan and the leader of Joint Special Operations Command, will deliver insights on leadership, as well as his life experiences both personally and on the battlefield, to the dinner’s attendees.
This year’s 12th annual NACDS Foundation dinner will be held Nov. 30 in New York.
“We are honored to have distinguished military leader General Stanley McChrystal as the keynote speaker for this year’s NACDS Foundation dinner,” said NACDS Foundation president Edith Rosato. “His service to his country for 34 years demonstrates his career-commitment to the safety of the American people.”
Warner Chilcott acquires rights to Enablex
ARDEE, Ireland Drug maker Warner Chilcott will buy the U.S. rights to a treatment for overactive bladder for $400 million, the company said Friday.
The drug maker announced that it would terminate its co-promotion agreement with Novartis concerning the drug Enablex (darifenacin) and purchase the rights to sell it in the United States. It may be required to make additional milestone payments of up to $20 million to Novartis.
“This is an important step in expanding our presence in one of our key therapeutic segments,” Warner Chilcott president and CEO Roger Boissonneault said. “The acquisition of the U.S. rights to Enablex bolsters our franchise in the urology segment, provides us with greater control in promoting the product and demonstrates our ability to successfully add complementary assets to an already strong product portfolio.”
To finance the deal and other corporate expenses, Warner Chilcott also said Friday it would issue bonds worth $500 million.